Who is sponsoring NCT06116968?

NCT06116968 is sponsored by Corxel Pharmaceuticals.

What drugs are being tested in NCT06116968?

Interventions in NCT06116968: Aficamten.

What condition does NCT06116968 study?

NCT06116968 studies Obstructive Hypertrophic Cardiomyopathy.

Is NCT06116968 still recruiting?

NCT06116968 is currently completed. Last updated 21 January 2026.

Last reviewed 2026-01-21 · How we verify

NCT06116968

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Completed Phase 3 Last updated 21 January 2026

What this trial tests

Phase 3 trial testing Aficamten in Obstructive Hypertrophic Cardiomyopathy in 40 participants. Completed in 20 October 2025.

Timeline

14 November 2023

Primary endpoint
20 October 2025

20 October 2025

Quick facts

Lead sponsor	Corxel Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	14 November 2023
Primary completion	20 October 2025
Estimated completion	20 October 2025
Sites	12 locations across China

Drugs / interventions tested

Aficamten — full drug profile →

Conditions studied

Obstructive Hypertrophic Cardiomyopathy — all drugs for Obstructive Hypertrophic Cardiomyopathy →

Sponsor

Corxel Pharmaceuticals — full company profile →

Who can join

Adults 18 to 85, any sex, with Obstructive Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.
Davis BJ, Volk H, Nguyen O, Kamna D, et al · · 2025 · cited 9× · PMID 40055855 · DOI 10.1161/jaha.124.038758
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.
Tamargo J, Agewall S, Ambrosio G, Borghi C, et al · · 2025 · cited 6× · PMID 40058879 · DOI 10.1093/ehjcvp/pvaf012

Verify or expand the search:

Other trials of Aficamten

Trials testing the same drug.

NCT05924815 — Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval · Phase 1 · completed

Other recruiting trials for Obstructive Hypertrophic Cardiomyopathy

Currently open trials in the same condition.

NCT07023341 — A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic · Phase 3 · active not recruiting
NCT06146660 — A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy · recruiting
NCT06551129 — Real-world Patient Reported Outcomes Among Patients Treated With Camzyos · recruiting
NCT06023186 — Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM · recruiting
NCT05489705 — A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes · recruiting

Other Corxel Pharmaceuticals trials

Trials by the same sponsor.

NCT07340320 — A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus · Phase 2 · recruiting
NCT07011797 — A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants · Phase 2 · active not recruiting
NCT06990867 — Optimizing Reperfusion to Improve Outcomes and Neurologic Function · Phase 2, PHASE3 · recruiting
NCT06270030 — Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presby · Phase 1 · completed
NCT06045299 — Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06116968 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Corxel Pharmaceuticals
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06116968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing